Dashboard
Manage Tickers

JNJ


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

freedom-capital-markets-downgrades-johnson--johnson-to-hold-raises-price-target-to-190
Freedom Capital Markets Downgrades Johnson...
10/22/2025 14:56:57

Freedom Capital Markets analyst Ilya Zubkov downgrades Johnson & Johnson (NYSE:JNJ) from Buy to Hold and raises the pric...

johnson--johnsons-inlexzo-plus-cetrelimab-delivers-strong-pre-surgical-results-in-patients-with-muscle-invasive-bladder-cancer-scheduled-for-radical-cystectomy-phase-2b-sunrise-4-study-shows-38-of-patients-treated-with-inlexzo-based-combination-had-no-detectable-cancer-in-the-bladder-prior-to-surgery-data-support-potential-role-of-inlexzo-in-treating-muscle-invasive-bladder-cancer
Johnson & Johnson's INLEXZO Plus Cetrelima...
10/20/2025 13:09:31

https://www.jnj.com/media-center/press-releases/johnson-johnsons-inlexzo-gemcitabine-intravesical-system-plus-cetrelimab-delive...

reported-sunday-johnson--johnson-notes-45-overall-response-rate-72-month-median-duration-of-response-and-68-month-progression-free-survival-with-subcutaneous-amivantamab-in-metastatic-head-and-neck-cancer
Reported Sunday, Johnson & Johnson Notes 4...
10/20/2025 07:18:54

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patientsNew findings from this investigatio...

johnson--johnson-reports-strong-phase-3-results-for-multiple-myeloma-therapy
Johnson & Johnson Reports Strong Phase 3 R...
10/16/2025 17:37:03

Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson...

Core News & Articles
Reported Earlier: 'J&J Faces First UK Laws...
10/16/2025 15:25:41

https://www.reuters.com/sustainability/boards-policy-regulation/jj-faces-first-uk-lawsuits-alleging-its-baby-powder-caused-canc...

johnson--johnson-kenvue-named-in-first-ever-uk-legal-action-over-talc-cancer-claims
Johnson & Johnson, Kenvue Named In First E...
10/16/2025 14:18:35

Johnson & Johnson faces 3,000 UK lawsuits alleging asbestos-contaminated talcum powder caused cancer and concealed risks fo...

johnson--johnson-reportedly-faces-major-uk-lawsuit-over-baby-powder-cancer-risks
Johnson & Johnson Reportedly Faces Major U...
10/16/2025 13:09:59

A legal claim involving 3,000 people has been reportedly filed against Johnson & Johnson (NYSE: JNJ) in the U.K., alleging ...

johnson--johnsons-phase-3-majestec-3-trial-becomes-first-to-show-statistically-significant-progression-free-and-overall-survival-benefit-for-investigational-tecvayli--darzalex-faspro-combo-in-relapsedrefractory-multiple-myeloma-as-early-as-second-line-idmc-recommended-unblinding-the-study-based-on-statistically-significant-results
Johnson & Johnson's Phase 3 MajesTEC-3 Tri...
10/16/2025 12:14:17

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multipl...

scott-bessent-says-us-investment-boom-sustainable-under-trump-the-only-thing-slowing-us-down
Scott Bessent Says US Investment Boom 'Sus...
10/16/2025 12:05:56

U.S. Treasury Secretary Scott Bessent credited the country's investment boom to President Donald Trump's policies on We...

these-analysts-boost-their-forecasts-on-johnson--johnson-after-upbeat-q3-earnings
These Analysts Boost Their Forecasts On Jo...
10/15/2025 18:04:28

johnson--johnson-rules-out-big-acquisitions-reiterates-focus-on-small-deals-analyst
Johnson & Johnson Rules Out Big Acquisitio...
10/15/2025 17:56:28

Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing...

Core News & Articles
New Jersey Rep. Thomas Kean Sold Up to $21...
10/15/2025 15:00:15

citigroup-maintains-buy-on-johnson--johnson-raises-price-target-to-215
Citigroup Maintains Buy on Johnson & Johns...
10/15/2025 14:56:52

Citigroup analyst Joanne Wuensch maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $213...

stifel-maintains-hold-on-johnson--johnson-raises-price-target-to-190
Stifel Maintains Hold on Johnson & Johnson...
10/15/2025 14:40:58

Stifel analyst Rick Wise maintains Johnson & Johnson (NYSE:JNJ) with a Hold and raises the price target from $165 to $190.

raymond-james-maintains-outperform-on-johnson--johnson-raises-price-target-to-209
Raymond James Maintains Outperform on John...
10/15/2025 14:20:47

Raymond James analyst Jayson Bedford maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price targe...

morgan-stanley-maintains-equal-weight-on-johnson--johnson-raises-price-target-to-190
Morgan Stanley Maintains Equal-Weight on J...
10/15/2025 13:08:30

Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price tar...

b-of-a-securities-maintains-neutral-on-johnson--johnson-raises-price-target-to-204
B of A Securities Maintains Neutral on Joh...
10/15/2025 12:26:27

B of A Securities analyst Tim Anderson maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target...

looking-at-johnson--johnsons-recent-unusual-options-activity
Looking At Johnson & Johnson's Recent Unus...
10/14/2025 19:01:48

ubs-maintains-buy-on-johnson--johnson-raises-price-target-to-214
UBS Maintains Buy on Johnson & Johnson, Ra...
10/14/2025 16:06:49

UBS analyst Danielle Antalffy maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $190 to...

johnson--johnson-cfo-joseph-wolk-says-2026-adj-eps-expected-to-exceed-current-street-estimates-by-as-much-as-5-cents
Johnson & Johnson CFO Joseph Wolk Says 202...
10/14/2025 13:14:19

- Conf Call

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION